Nidrazid (Isoniazid)

Isoniazid, the active ingredient in Nidrazid, is an antitubercular agent presented as an oral tablet for oral use. It is used to treat active tuberculosis in adults and children as part of combination therapy.

GNH USA supplies Nidrazid as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Nidrazid is manufactured in accordance with EU pharmacopeial specifications and is available for export to regulated markets.

Isoniazid is an antitubercular agent used in the management of Mycobacterium tuberculosis infection.

- Active tuberculosis: eliminates replicating Mycobacterium tuberculosis when combined with other anti‑TB drugs. - Latent tuberculosis infection: reduces risk of progression to active disease when given as preventive monotherapy. - TB prophylaxis in high‑risk contacts: provides chemoprophylaxis to prevent infection after exposure.

Isoniazid may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Loss of appetite: decreased food intake. - Peripheral neuropathy: tingling or numbness in hands and feet.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or hepatitis. - Severe hypersensitivity reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hemolytic anemia: especially in patients with G6PD deficiency.

When prescribing isoniazid, clinicians should consider several precautionary measures to minimize risk.

- Baseline liver function: assess hepatic enzymes before initiating therapy. - Monitor liver enzymes: repeat testing periodically during treatment. - Vitamin B6 supplementation: co‑administer pyridoxine to reduce neuropathy risk. - Assess for G6PD deficiency: avoid use in patients with known deficiency. - Pregnancy and lactation: evaluate risk‑benefit; use only if clearly needed. - Store at ambient temperature: keep below 25°C in original packaging, protect from moisture.

Isoniazid interacts with several medicines, affecting their metabolism or increasing toxicity.

Major Interactions (Avoid): - Rifampicin: reduces isoniazid plasma levels, compromising efficacy. - Phenytoin: accelerates isoniazid metabolism, decreasing therapeutic effect. - Alcohol: combined use heightens risk of hepatotoxicity.

Moderate Interactions (Monitor Closely): - Acetylsalicylic acid (aspirin): may increase risk of liver injury. - Antiretroviral drugs (e.g., efavirenz): may require dose adjustments. - Warfarin: isoniazid can potentiate anticoagulant effect, monitor INR.